Blueprint Medicines clinical trial pipeline

4 trials changed in the last 30 days: 0 stopped, 0 with notable changes, 4 with minor changes only.

1. Minor

   (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263…(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo · Indolent Systemic Mastocytosis

   Trial sites expanded: 76 → 88 locations

   Blueprint Medicines Corporation·Phase 2/3· NCT04910685· Registry history of NCT04910685 on ClinicalTrials.gov (opens the registry)

   Updated Oct 7, 2026

2. Minor

   POLARIS · Screening Study for KIT D816V Mutated Mast Cell…POLARIS · Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations

   Trial sites expanded: 22 → 26 locations

   Blueprint Medicines Corporation·Not specified· NCT07143669· Registry history of NCT07143669 on ClinicalTrials.gov (opens the registry)

   Updated Oct 7, 2026

3. Minor

   Non-Interventional Study · Indolent Systemic Mastocytosis (ISM) in…Non-Interventional Study · Indolent Systemic Mastocytosis (ISM) in Germany

   Trial sites expanded: 8 → 12 locations

   Blueprint Medicines Corporation·Not specified· NCT07255638· Registry history of NCT07255638 on ClinicalTrials.gov (opens the registry)

   Updated Oct 7, 2026

4. Minor

   BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS…BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

   Trial sites expanded: 3 → 16 locations

   Blueprint Medicines Corporation·Phase 1/2· NCT07629960· Registry history of NCT07629960 on ClinicalTrials.gov (opens the registry)

   Updated Sep 21, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.